The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...
The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...
The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...
The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...
PUNE, India, July 9, 2025 /PRNewswire/ -- According to Credence Research, the global Spine Degenerative Disk Disease Treatment Market was valued at USD 22,272.2...
PUNE, India, July 9, 2025 /PRNewswire/ -- According to Credence Research, the global Spine Degenerative Disk Disease Treatment Market was valued at USD 22,272.2...
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...
Oversubscribed round was led by Future Ventures, and included NFX, BOLD Capital Partners, Kendall Capital Partners, Amplify Partners, Base4 Capital and others
Dr. Emilio Emini, former SVP of...
The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency,...
PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.
From award-winning skincare products to first aid, hydration, sunscreen, and bug bite relief, FSAs and HSAs help families and individuals make the most of summer fun...